Please login to the form below

Not currently logged in
Email:
Password:

Lantus shows no retinopathy progression risk

Sanofi-aventis has announced the results a five-year study of Lantus on progression of retinopathy in patients with type 2 diabetes

Sanofi-aventis has announced the results a five-year study of Lantus (insulin glargine [DNA] injection) versus NPH insulin on progression of retinopathy in patients with type 2 diabetes. The findings of this, the longest controlled study ever reported using insulin glargine, were published online in Diabetologia and showed similar effects on retinopathy and overall safety in the two treatment groups. 

Diabetic retinopathy is a progressive disease that results from cellular proliferation within the eye and is a major cause of blindness in patients with diabetes. In the study of patients with retinopathy, the progression of diabetic retinopathy was similar in the two treatment groups over the long-term course of treatment. This indicates that Lantus does not have mitogenic effects different from the human NPH insulin within the eye. Dr Julio Rosenstock, director of the Dallas Diabetes and Endocrine Center at Medical City and clinical professor of medicine, University of Texas Southwestern Medical School explains: "The study demonstrated no evidence of a greater risk of progression of retinopathy with insulin glargine."

The results follow recent publicity concerning questions raised over the safety of insulin analogues. On June 25, the European Association for the Study of Diabetes (EASD) made an urgent call for more research into a possible link between use of Lantus and the increased risk of cancer, and the European Medicines Agency (EMEA) is looking into four recently published registry studies that investigate a possible relationship between insulin analogues, in particular insulin glargine, and the risk of cancer. The studies, which showed inconsistent results, were published on the Diabetologia website on June 26, 2009.

6th July 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics